282 related articles for article (PubMed ID: 8383846)
21. [Prognostic factors in breast cancer and their consequences for therapeutic decisions].
Graeff H; Jänicke F
Chirurg; 1992 Jun; 63(6):461-8. PubMed ID: 1643982
[No Abstract] [Full Text] [Related]
22. [Morphologic and morphometric parameters of infiltrating duct carcinoma of the breast and receptor state in fluorescence: correlations in 104 cases (1983 case survey)].
Tunesi G; Anselmi L; Bandelloni R; Gambini C; Reale A; Sementa AR; Bronzini E
Pathologica; 1985; 77(1049):251-8. PubMed ID: 3008066
[No Abstract] [Full Text] [Related]
23. Estrogen and progesterone receptors in primary eccrine carcinoma.
Voytek TM; Ricci A; Cartun RW
Mod Pathol; 1991 Sep; 4(5):582-5. PubMed ID: 1661896
[TBL] [Abstract][Full Text] [Related]
24. [Comparison of the receptor content and growth fraction of breast cancers and their axillary lymph node metastases].
Fleige B; Pickartz H; Stein H
Pathologe; 1989 Jan; 10(1):12-5. PubMed ID: 2646629
[No Abstract] [Full Text] [Related]
25. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rosser RJ
Cancer; 2003 Sep; 98(5):1102-3; author reply 1103. PubMed ID: 12942582
[No Abstract] [Full Text] [Related]
26. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
Seifert M; Wierrani F; Kubista E; Spona J
Gynakol Rundsch; 1991; 31 Suppl 2():397-8. PubMed ID: 1790992
[No Abstract] [Full Text] [Related]
27. [Inflammatory breast cancers: correlation between anatomopathology and steroid receptor assay].
Mauriac L; Wafflart J; Trojani M; Durand M
Bull Cancer; 1983; 70(3):160-4. PubMed ID: 6309290
[TBL] [Abstract][Full Text] [Related]
28. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
[No Abstract] [Full Text] [Related]
29. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
30. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
31. [Estrogen receptors and clinical prognostic factors in breast cancer].
Hernández JL; Lera JM; Fakih A; Gómez Portilla A; Vicente F; Zornoza G
Rev Esp Oncol; 1983; 30(2):179-88. PubMed ID: 6097962
[TBL] [Abstract][Full Text] [Related]
32. [Cytology of breast cancer correlated with biochemically determined hormone sensitivity].
Yilmaz H; Labenski R; Jungblut PW; Ries P
Verh Dtsch Ges Pathol; 1985; 69():549-51. PubMed ID: 4096125
[No Abstract] [Full Text] [Related]
33. Estrogen dependence of primary breast cancer--correlation with histologic type and grade.
Nikolić-Vukosavljević D; Branković-Magić M; Polić D; Vlajić M; Vuletić L; Spuzić I
Neoplasma; 1992; 39(5):299-304. PubMed ID: 1436244
[TBL] [Abstract][Full Text] [Related]
34. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
35. [Estrogen receptor (ER), progesterone receptor (PR)].
Sawada T; Sakayori N
Nihon Rinsho; 2005 Aug; 63 Suppl 8():762-4. PubMed ID: 16149634
[No Abstract] [Full Text] [Related]
36. [Interpretation of the estrogen receptor content of breast cancer].
Tuczek HV; Fritz P; Oeffinger B; Limbach HJ; Mischlinski A; Klein C; Wegner G
Geburtshilfe Frauenheilkd; 1990 Apr; 50(4):314-8. PubMed ID: 2358183
[TBL] [Abstract][Full Text] [Related]
37. [Correlation between morphology and steroid receptors in breast cancer].
Hanselmann R; Genton CY
Pathologe; 1983 Jan; 4(1):17-23. PubMed ID: 6844281
[No Abstract] [Full Text] [Related]
38. [Immunohistochemical detection of estrogen and progesterone receptors in paraffin sections].
Snijders M; Theunissen P; Debets-Te Baerts M; Koudstaal J
Pathologe; 1990 Jul; 11(4):236-9. PubMed ID: 2204912
[No Abstract] [Full Text] [Related]
39. [Expression of steroid receptors and DNA synthesis in male breast cancer].
Petroni S; Mangia A; D'Amico C; Simone G
Pathologica; 2003 Feb; 95(1):31-6. PubMed ID: 12735283
[TBL] [Abstract][Full Text] [Related]
40. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
